Meridian Funds, managed by ArrowMark Partners, released its fourth-quarter 2025 investor letter for “Meridian Small Cap ...

About Septerna Septerna, Inc. is a clinical-stage biotechnology company with a world-class team of GPCR experts and drug developers advancing cutting-edge science to unlock the full potential of GPCR ...

Structure Therapeutics Inc. is emerging in oral GLP-1 obesity drugs after Phase II success and rivals’ setbacks. Click here ...

G-protein-coupled receptors (GPCRs) are one of the largest families of cell surface proteins in the human body that recognize hormones, neurotransmitters, and drugs. These receptors regulate a wide ...

Q4 2025 Earnings Call February 24, 2026 5:00 PM ESTCompany ParticipantsTryn Stimart - Chief Legal Officer, CCO, ...

Tectonic Therapeutic, Inc. (NASDAQ: TECX) ("Tectonic"), a clinical-stage biotechnology company focused on the discovery and development of therapeutic ...

New company established by a leading international life sciences investment firm Tokyo, Japan and Cambridge, UK, 12 January ...

Structure Therapeutics develops oral therapies for chronic diseases, using a proprietary platform to target G-protein-coupled receptors.

Immuno-oncology and inflammation startup Kainova Therapeutics has announced the successful first close of its Series B financing round totaling $32 million CAD ($23.6 million).

Pramorelin, also known in scientific literature as a synthetic ghrelin receptor agonist, has emerged as a notable peptide within the broader landscape of endocrine and metabolic research. Its primary ...

G-protein-coupled receptors (GPCRs) are one of the largest families of cell surface proteins in the human body that recognize hormones, neurotransmitters, and drugs. These receptors regulate a wide ...

Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that the company will present data from ...